Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports Third Quarter 2017 Financial Results
NexoBrid ® sales grow 74% year-to-date Raised gross proceeds of $25.2 million through public equity offering Awarded additional $32 million from BARDA to support NexoBrid R&D programs Conference call begins today at 8:30 a.m. Eastern Standard Time YAVNE, Israel , Nov.
View HTML
Toggle Summary Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound Weighing an Appeal
YAVNE, Israel , Nov. 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Tel Aviv District Court ordered that MediWound (the
View HTML
Toggle Summary MediWound to Host Third Quarter 2017 Financial Results Conference Call on November 16, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel , Nov. 10, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the nine
View HTML
Toggle Summary MediWound Announces Exercise of Underwriters’ Option to Purchase Additional Shares
YAVNE, Israel , Oct. 27, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the underwriters of its previously announced
View HTML
Toggle Summary MediWound Appoints Mr. Stephen T. Wills as Chairman to its Board of Directors
YAVNE, Israel , Oct. 25, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Stephen T.
View HTML
Toggle Summary MediWound Further Expands NexoBrid's® Global Outreach through New Distribution Agreement in Taiwan with Holy Stone Healthcare
YAVNE, Israel , Oct. 16, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in the development of innovative therapies to address unmet needs in severe burn and wound management, today announced an agreement with Holy Stone Healthcare,
View HTML
Toggle Summary MediWound Ltd. Announces Pricing of $22 Million Public Offering of Ordinary Shares
YAVNE, Israel , Sept. 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) today announced the pricing of an underwritten public offering of 4,400,000 of its ordinary shares at a price to the public of $5.00 per share. All of the ordinary shares are being offered by MediWound .
View HTML
Toggle Summary MediWound Ltd. Announces Public Offering of Ordinary Shares
YAVNE, Israel , Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that it has commenced an underwritten public offering of its
View HTML
Toggle Summary MediWound's NexoBrid® Wins Best Poster Presentation Award at the 17th European Burns Association Congress
Award-winning Poster Underscores European Consensus on Benefits of NexoBrid YAVNE, Israel , Sept. 11, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management,
View HTML
Toggle Summary MediWound's NexoBrid® Highlighted in 43 Presentations at the 17th European Burns Association Congress
Burn Experts from across Europe will share their NexoBrid Experience in 2 Plenary Sessions; 23 Oral Presentations and 18 Poster Presentations
View HTML